Vimarsana
Biggest News Aggregation in the World

Alpha Wave Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpha Wave Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpha Wave Ventures Today - Breaking & Trending Today

Biolinq Raises $58M in Funding - Vimarsana News

Biolinq Raises $58M in Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Chipmaker Cerebras Systems Picks Citigroup for IPO - Vimarsana News

Chipmaker Cerebras Systems Picks Citigroup for IPO

(Bloomberg) -- Chipmaking startup Cerebras Systems Inc. has picked Citigroup Inc. as the lead bank on its initial public offering, according to people familiar with the matter.Most Read from BloombergTrump Sues Truth Social Company Co-Founders to Zero Them OutA Million Simulations, One Verdict for US Economy: Debt Danger AheadTrump Media’s Business Doesn’t MatterTrump Got His $175 Million Bond From a Billionaire Fan’s CompanyTesla’s Sales Miss by the Most Ever in Brutal Blow for EVsThe Silicon V

Source: yahoo.com
Lose Fat, Not Muscle: Next Test for Lilly's Zepbound Pairs It With BioAge Drug - Vimarsana News

Lose Fat, Not Muscle: Next Test for Lilly's Zepbound Pairs It With BioAge Drug

In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.

gamma. Announces New Funding Partner Alpha Wave Global to Cap Off a Year of Momentum and Expansion - Vimarsana News

gamma. Announces New Funding Partner Alpha Wave Global to Cap Off a Year of Momentum and Expansion

LOS ANGELES--(BUSINESS WIRE)--Feb 1, 2024--

Cour gets $105M, pharma help to 'reprogram' autoimmune disease - Vimarsana News

Cour gets $105M, pharma help to 'reprogram' autoimmune disease

BioPharma